| Towards Life-Long Healthy Lungs: A Multidisciplinary Follow-up Framework for Preterm Infants (NCT05618769) | Franciscus Gasthuis | 2022-07-18 |
| Impact of the Covid-19 on RSV (NCT05348616) | Hospices Civils de Lyon | 2022-05-01 |
| Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age (NCT04520659) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-16 |
| Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment (NCT05268939) | LumiraDx UK Limited | 2022-01-04 |
| Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) (NCT04938830) | Merck Sharp & Dohme LLC | 2021-11-30 |
| Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults (NCT05118386) | Gates Medical Research Institute | 2021-11-16 |
| Severity of RSV Infections in Twins (NCT05070975) | Hospices Civils de Lyon | 2021-11-05 |
| Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test (NCT04782336) | LumiraDx UK Limited | 2021-06-30 |
| Impact of the Covid-19 on Respiratory Syncytial Virus (RSV) Epidemic (NCT04944160) | Hospices Civils de Lyon | 2021-03-15 |
| Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects (NCT04871724) | Enanta Pharmaceuticals, Inc | 2021-03-12 |
| Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults (NCT04752644) | Bavarian Nordic | 2021-02-22 |
| RSV Burden in Outpatient and Hospital Settings (NCT04743609) | Association Clinique Thérapeutique Infantile du val de Marne | 2021-02-08 |
| Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine (NCT04690335) | Meissa Vaccines, Inc. | 2020-12-29 |
| Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children (NCT04484935) | AstraZeneca | 2020-08-19 |
| Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV (NCT04267822) | Pfizer | 2020-06-15 |
| Respiratory Syncytial Virus Infection May be More Dangerous in Neonate (NCT04531735) | Dr. Behcet Uz Children's Hospital | 2020-03-01 |
| Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room (NCT05105191) | Erasme University Hospital | 2020-02-03 |
| Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants (NCT04144816) | Hospices Civils de Lyon | 2019-10-01 |
| Emission Patterns of Respiratory Syncytial Virus (NCT03909867) | Wake Forest University Health Sciences | 2019-09-17 |
| RSV Study in Adults 60 to 75 Years of Age (NCT03919591) | Hvivo | 2019-03-12 |
| Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects (NCT03755778) | Enanta Pharmaceuticals, Inc | 2018-11-29 |
| The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus (NCT03728413) | Imperial College London | 2018-11-12 |
| Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects (NCT03750383) | Enanta Pharmaceuticals, Inc | 2018-11-02 |
| A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model (NCT03691623) | Enanta Pharmaceuticals, Inc | 2018-10-15 |
| Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children (NCT03596801) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-29 |
| A Study of EDP-938 in Healthy Subjects (NCT03384823) | Enanta Pharmaceuticals, Inc | 2017-12-07 |
| Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children (NCT03387137) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-13 |
| RESCEU: Defining the Burden of RSV Disease (NCT03698084) | University of Oxford | 2017-09-05 |
| RESCEU Study, Defining the Burden of Disease of RSV in Older Adults (NCT03621930) | UMC Utrecht | 2017-08-01 |
| RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants (NCT03627572) | UMC Utrecht | 2017-07-21 |
| Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis (NCT03062917) | Imperial College Healthcare NHS Trust | 2015-10-02 |
| Effect of Heliox on RSV Bronchiolitis (NCT03171142) | Wael Seliem | 2015-05-01 |
| ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers (NCT01875926) | Ablynx, a Sanofi company | 2013-05-01 |
| A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806 (NCT01801293) | Gilead Sciences | 2013-03-01 |
| ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers (NCT01483911) | Ablynx, a Sanofi company | 2011-11-01 |
| Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV) (NCT01475305) | MedImmune LLC | 2011-10-20 |
| Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study (NCT01090557) | Winthrop University Hospital | 2007-10-01 |